Michael Fisher

Former Director-Automation & Systems Validation at Takeda Oncology Co.

Michael Fisher

Michael Fisher

Former Director-Automation & Systems Validation at Takeda Oncology Co.

RelSci Relationships



Former Director-Finance & Treasurer at AutoImmune, Inc.

President at Pasadena Bioscience Collaborative

Co-Founder at Lexicon Pharmaceuticals, Inc.

Director at Safe Hydrogen LLC

Former Biochemistry Director at AutoImmune, Inc.

Former Director-Regulatory Affairs & Quality Assurance at Diatech Pharmacogenetics SRL

Former Vice President-Manufacturing Operations at Boston Scientific Corporation

Former Senior Vice President & General Counsel at Apple, Inc.

Co-Founder at Apposite Capital LLP

Chairman & Chief Executive Officer at ContraFect Corp.

Subscribe to RelSci Professional to see 359 more Relationships
Paths to Michael Fisher
Potential Connections via
Relationship Science
Michael Fisher
Former Director-Automation & Systems Validation at Takeda Oncology Co.

UMass Amherst, the flagship campus of the University of Massachusetts system, sits on nearly 1,450-acres in the scenic Pioneer Valley of Western Massachusetts, 90 miles from Boston and 175 miles from New York City. The campus provides a rich cultural environment in a rural setting close to major urban centers.

Worcester Polytechnic Institute was founded in 1865 to create and convey the latest science and engineering knowledge in ways that are most beneficial to society. WPI's 14 academic departments offer more than 50 undergraduate and graduate degree programs in science, engineering, technology, business, the social sciences, and the humanities and arts, leading to bachelor’s, master’s, and doctoral degrees.

Career History
Director-Automation & Systems Validation
2001 - 2003

Takeda Oncology Co. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Director-Manufacturing Operations
1998 - 1999

AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA.

Validation Manager
1996 - 1998

Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease.It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs.In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis.It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing.The Company was founded on March 2, 1988 and is headquartered in Worcester, MA.

Subscribe now for extended career history